Bradykinin (BK) is a peptide mediator released in inflammation that potently excites sympathetic neurons. We have studied the mechanism of this excitation in dissociated rat sympathetic neurons and found that at low nanomolar (ECs0 = 0.9 nM) concentrations, BK inhibited the M-type K + current IK(M). Studies with the selective antagonist Hoe140 revealed that this effect was mediated via the B2 receptor subtype, and mRNA encoding this receptor was identified in these neurons by RT-PCR. Ix(M) inhibition was unaffected by Pertussis toxin or microinjection of antibodies to Gao but was selectively in hibited by microinjection of antibodies to G~q~11. Thus, BK is the most potent M current inhibitor yet described in mammalian neurons, and BK inhibition of M current is mediated by a G protein pathway similar to that activated by muscarinic acetylcholine receptors.
Introduction
The nonapeptide bradykinin (BK) is formed from plasma protein precursors following tissue injury and is considered an important mediator of inflammation and hyperalgesia (Lewis, 1970; Regoli and Barab6, 1980; Hall, 1992; Dray and Perkins, 1993) . There is evidence that activation of sympathetic nerves may contribute to some of its effects, including hyperalgesia and plasma extravasation, as these are abolished by sympathectomy (Levine et al., 1986; Coderre et al., 1989; Lee et al., 1991) . Such effects are thought to be mediated by a stimu[atory action of BK on sympathetic terminals, resulting in the release of prostanoids (Coderre et al., 1989; Lee et al., 1991) , which can then induce sensitization of nociceptors (see Dray and Perkins, 1993) . There has also been speculation that BK may have an involvement in the etiology of sympathetically maintained pain (McMahon, 1991) .
The ability of BK to stimulate sympathetic neurons was described many years ago (Lewis and Reit, 1965, 1966; Trendelenburg, 1966) , but the mechanism of this stimulation is unknown. Studies on other neurons and neural cell lines suggest a number of possibilities, including activation of a cation conductance ('l'ertoolen et al., 1987; Burgess et al., 1989; Neuhaus et al., 1991) , activation of a Ca2÷-dependent CI-conductance (Dunn et al., 1991) , which would be expected to depolarize rat sympathetic neurons (Adams and Brown, 1975) , inhibition of a Ca 2÷-dependent K ÷ conductance (Weinreich, 1986) , and inhibition of the M-type voltage-gated K ÷ conductance (Higashida andBrown, 1986 Villarroel et al., 1989) .
In the present experiments, we have examined the excitatory action of BK on dissociated rat sympathetic neurons. We find that it is an extremely potent inhibitor of the M current (IKIM)), and that it works in a qualitatively similar, but quantitatively and kinetically different, manner to muscarinic acetylcholine receptor stimulants.
Results

Excitation and M Current Inhibition by Low Concentrations of BK
In current-clamp studies, the average resting potential in our sample of rat cultured superior cervical ganglion (SCG) neurons was -56 mV -4-1 mV (n = 37). BK produced a small (4-6 mV) depolarization of SCG neurons and induced repetitive action potential discharges during injection of depolarizing current (Figure 1 ). This accords with the excitatory effect of BK previously noted in cat (Haefely, 1970) and rabbit (Wallis and Woodward, 1974) SCG. This response is reminiscent of that seen with rnuscarinic acetylcholine receptor agonists (Brown and Constanti, 1980) and suggests that BK might inhibit IKIM~ (Constanti and Brown, 1981) . Consistent with this idea, in voltage-clamp experiments with the holding potential at about -25 mV (where there was a standing outward current), application of low nanomolar concentrations of bradykinin produced a slowly developing reduction of this outward current ( Figure  2A ). This BK-induced change in current was larger at depolarized potentials than at hyperpolarized potentials, implying a fall in effective input conductance (Figure 3 ). Inspection of current records obtained during hyperpolarizing voltage steps revealed that the BK effect was associated with inhibition of the voltage-gated K ÷ current IK(M), since the slow relaxations during deactivation and reactivation of this current were reduced ( Figure 2B ; see Adams et al., 1982) . In accordance with this, the currentvoltage curves (Figure 3 ) showed a reduction of the outward rectification normally observed at potentials positive to -70 mV (the threshold for IK/M) activation). In currentvoltage relationships, we observed small (< 100 pA) inward currents in response to 1 nM BK at potentials more negative than -70 mV (three of five cells) and small (<50 pA) outward currents in the remaining two cells. Thus, it appears that inhibition of outward IK(M) accounts for a very substantial proportion of the apparent inward current produced by BK, as this was itself highly voltage sensitive (Figure 3) .
These effects parallel those of muscarinic acetylcholine The left trace (control) shows a record of membrane potential of an SCG neuron recorded in current clamp using the perforated-patch technique. Injection of depolarizing current (0.3 nA for 500 ms, at the arrow) depolarized the neuron and evoked a single action potential. Application of 10 nM BK produced a small depolarization (5 mV in this cell), which was countered by injection of hyperpolarizing current sufficient to return the cell to its original resting membrane potential (-67 mV). When the same depolarizing current was injected in the presence of BK, repetitive action potential firing was seen (right trace). This recording was made from a cell maintained at 32°C. Action potential amplitudes are truncated by the digitization sampling rate (3 kHz).
receptor agonists, such as muscarine or oxotremorine-M (oxo-M), previously reported in these neurons (Constanti and Brown, 1981; Marrion et al., 1989; Bernheim et al., 1992; Caulfield et al., 1994) . However, there were two differences between the actions of BK and oxo-M. First, the effects of BK were much slower in onset. Thus, in five experiments in which BK (10 nM) and oxo-M (3 I~M) were directly compared, the half-times for reduction in outward currents at a holding potential of -25 mV were 22 _+ 2.5 s for BK and 7.5 _ 0.4 s for oxo-M. This did not seem to be due to slow equilibration, since (in four of these five cells) the initial response to BK was a small outward current that developed as rapidly as the response produced by oxo-M (which was purely a reduction in standing outward current; see Figure 2C ). The BK-induced outward current was not studied further because of its small size and irregular occurrence. Second, compared with recovery from oxo-M, recovery from inhibition of IKIM) by BK was frequently slow and incomplete, especially at higher concentrations (see Figure 2A ; Caulfield et al., 1994) . Inhibition of IK(M) by BK was evident at concentrations as low as 0.1 nM, with a plateau at 10-30 nM. The computed maximum inhibition was 74.1% __. 10.5% , with halfmaximum inhibition at 0.9 nM ( Figure 4A ). The rate of onset of IK(M) inhibition by BK was also concentration dependent; the half-time to the full development of the BK effect being approximately 40 s for 1 nM BK, and approximately 20 s for 10 nM BK ( Figure 4B ). The concentrationeffect curve for inhibition of IK(M) by BK in Figure 4 was constructed by applying single concentrations of BK to individual cells, thereby minimizing errors due to waning reponses to repeated applications of BK on the same cell (tachyphylaxis). Tachyphylaxis was not significant at the lower range of the concentration-effect curve; for example, in five cells, the IK~M) inhibitions in response to two subsequent applications of 1 nM BK were 35.6% + 3.7% and 34.4% -+ 4.7% (n = 5). However, responses to higher concentrations of BK were not reproducible for a given cell; for example, in three cells, the IK(M)inhibition for a first application of 10 nM BK was 52.7% __+ 3.0%, whereas the inhibition with the second application was significantly lower (a mean of 35% of the first response; p < .01, paired t test). This contrasts with IK(Mi inhibition by a maximally effective concentration of oxo-M (3 pM; Caulfield et al., 1994) , in which a first application produced 84.3% _+ 5.7% reduction of current, whereas a second application elicited an almost identical response (83.3% _ 5.2%; n = 3). In control solution, the graph of evoked current overlapped data points obtained by estimating steadystate currents during discrete 1 s steps to command voltages within this range. This shows that this voltage ramp protocol gave an adequate measure of current over the activation range for IK<M) (more positive than -70 mV); both concentrations of BK reduced evoked current over this range. Also, the BK-sensitive current across this voltage range (obtained by subtraction of current in the presence of BK from control current) closely resembled the control current.
IK(M) Inhibition Is Mediated by the B2 Receptor
The effect of the highly selective B2 receptor antagonist Hoe140 was investigated by first estimating IK(M/inhibition in response to 1 nM BK, allowing recovery of IK(M) after washing out the BK, then repeating the application of 1 nM BK in the presence of the antagonist. Hoe140 (100 nM, applied for 5 min; n = 4) reduced the response to 1 nM BK by 91.8 % _+ 3.5% ( Figure 5 ). Usually, the BK response did not recover even after washing in antagonist-free solution for 30 min (n = 3), although partial reversal of the Hoe140 antagonism was observed in one cell after washing for 90 rain ( Figure 5 ). Reverse transcription-polymerase chain reaction (RT-PCR) analysis of RNA extracted from rat superior cervical ganglia and rat dorsal root ganglia, with primers derived from noncoding and coding exons of the rat BR2 gene, revealed the presence of BR2 transcripts in both tissues ( Figure 5C ).
B2 Receptor-Mediated Inhibition of IK(M) Involves
G.qm Protein(s)
In these experiments, we used a test concentration of 1 nM BK, as there was no waning of the response to this concentration of BK for a given cell or between cells in the same dish. Also, a submaximal response to 1 nM BK would be a sensitive assay for any change in receptor-G protein coupling efficiency. Inhibition of IK(MI by 1 nM BK (38.9% _+ 2.8%; n = 21) was not affected by pretreatment of neurons with Pertussis toxin (PTX; 500 ng/ml for 15-20 hr; 39.7% _+ 3.3% inhibition; n = 6) or injection of anti-Gao antibody (39.7% _+ 2.6% inhibition; n = 9). However, in neurons injected with anti-G.qm antibody, the BK inhibition of IK(MI was reduced to 19.5% _+ 5.8% (n = 6). This was a significant reduction compared with the BK response in anti-G~o injected neurons (p < .05, t test; Figure 6 ).
We also determined whether the inhibitory effect of the anti-G~qm antibody on IK/M/ inhibition by BK could be occluded by injecting a mixture of the antibody and the immu- 
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of IK(M)in the group injected with antibody pl us peptide was 23.5% _+ 4.4% (n --10; significantly greater than the antibody alone group, p < .05; Figure 7 ). The reversal of the antibody effect by immunogenic peptide was not complete, as BK inhibition in the peptide plus antibody injected cells was still significantly less (p < .05) than in cells injected with peptide alone. None of the above injection procedures affected the amplitude of IK(M) deactivation relaxations (mean amplitudes ranged from 152 pA to 228 pA, with standard errors of 11-22 pA).
nogenic peptide to preabsorb the anti-G~qm antibody. Injection of peptide alone (1 ~g/ml) did not affect the BK inhibition of IK(M) (40.1% --+ 5.0%; n = 9) when compared with either uninjected cells or cells injected with anti-Goo antibody. In this experimental series, injection of anti-G~qm antibody greatly reduced the BK response (5.9% _ 2.2% IK(M) inhibition; n --9; p < .001), and this effect of the anti-G~q~ antibody was partially reversed in cells injected with a combination of antibody and peptide; BK inhibition
Discussion
We have found that low nanomolar concentrations of BK inhibit IK(M)in rat sympathetic neurons. Current-voltage curves (see Figure 3 ) suggest that reduction of this outward current is the predominant BK effect. Therefore, IK(M) inhibition iS probably responsible for the ganglion excitation previously reported (Lewis and Reit, 1965, 1966; Trendelenburg, 1966; Haefely, 1970; Wallis and Woodward, 1974) and for the small depolarization and increase in action potential firing noted in the present experiments. This (open bar; n = 9) was significantly reduced (p < .001; asterisks) in neurons injected with anti-G~¢~ antibody (closed bar; n = 9). When peptide and antibody were injected together, the response to BK (hatched bar; n = 10) was significantly greater than in the antibodyalone group (p < 0.05; single asterisk).
is consistent with the action of BK previously observed in some neural cell lines, such as PC12 cells (Villarroel et al., 1989) and neuroblastoma-derived cells Brown, 1986, 1987) . However, our finding of this action of BK in sympathetic neurons may have direct relevance to the proposed role of the sympathetic nervous system in inflammatory processes (for review, see Dray and Perkins, 1993) . We obtained no evidence for activation of a substantial cation conductance, as has been reported in sensory neurons (Burgess et al., 1989; Dunn and Rang, 1990) . Although in some neurons, BK evoked a small inward current, this was inconsistent. Similar additional inward currents have been detected with agonists that inhibit M current in bullfrog sympathetic neurons (Jones, 1985) . In some neurons, the inward current resulting from IK(M)inhibition was preceded by a small outward current. This may have represented the Ca2---activated K ÷ current observed more prominently in neuroblastoma cells (Higashida and Brown, 1986) , but because of its small size and irregularity, we were unable to study this in detail.
There are two bradykinin receptors (B1 and B2) that could conceivably mediate BK inhibition of IK(M), although B1 receptors do not seem to be involved in normal physiological responses (Hall, 1992; Dray and Perkins, 1993) . Consistent with this, inhibition of IK/MI by BK in SCG neurons was mediated by the Bz receptor subtype, as evidenced by the potent inhibitory effect of the selective B2 receptor antagonist Hoe140 on BK responses. This conclusion is supported by our demonstration of the presence of mRNA encoding the B2 receptor in whole SCG, although we cannot exclude the possibility that some of this signal represents B2 mRNA expressed in cells other than the principal neurons.
Bradykinin receptors can couple to many biochemical pathways, via both PTX-sensitive and PTX-insensitive G proteins (Hall, 1992) . We suggest that the principal G protein mediating BK inhibition of IK(M) in SCG neurons is G°q or G,I~ (or both) because the BK response was significantly reduced in neurons that had been injected with an antibody raised against the C-terminal decapeptide sequence common to these G proteins. As this sequence is thought to represent the G-protein domain to which activated receptors couple, it is predicted that such antibodies will specifically inhibit responses mediated by the G proteins against which they are directed. The specificity of effect of the anti-G,~ antibodies in our study was indicated by a reduction in their efficacy when coinjected with a decapeptide corresponding to the immunogenic sequence. This would be expected to sequester the antibodies (if present in sufficient excess), thereby preventing their binding to endogenous G,qm in the SCG neurons. Further inferential evidence that IK(M) inhibition by BK is via G,,~I~ (rather than a PTX-sensitive G protein) comes from our parallel observation that the BK response was not modified by PTX pretreatment of SCG neurons or by injection of antibody raised against the C-terminal decapeptide of Goo. The lack of effect of these treatments cannot be attributed to incomplete action of PTX or to lack of activity of the anti-G,o antibody, as we have previously demonstrated virtually complete PTX-induced ADP-ribosylation of susceptible G proteins in SCG neurons and inhibition of a different neurotransmitter response (norepinephrine suppression of voltage-activated Ca 2+ current) by the anti-G,o antibody in these cells (Caulfield et al., 1994) . Our conclusion that the B2 bradykinin receptor couples to G~¢~ accords with previous demonstrations that stimulation of phospholipase C activity and activation of Ca2+-activated K ÷ conductance in NG108-15 neuroblastoma hybrid cells can be mediated by this G protein (Gutowski et al., 1991; WilkBlaszczak et al., 1994) .
Our finding that BK inhibits I(~M through G~qm is paralleled by similar findings for the M~ muscarinic acetylcholine receptor in SCG neurons (Caulfield et al., 1994) , perhaps suggesting that the BK response, like the muscarinic response (Selyanko et al., 1992) , is mediated by a diffusible messenger. However, there are a number of aspects of the BK IK(M) inhibition that are clearly different from the IK(M) inhibition produced by muscarinic receptor agonists.
Thus, the BK response has a significant onset latency (at least 10 s), is slow to develop (taking at least 60 s to asymptote), and reverses slowly and often incompletely. By contrast, IxiM) inhibition by oxo-M starts to develop soon after agonist application, reaches its maximum in 10-30 s, and usually reverses within 5 rain. In part, these differences might reflect a high binding affinity of bradykinin for its receptor with associated slow dissociation, which would result in slow onset of response. Thus, if it is assumed that the dissociation constant of BK for its receptor is 1 nM (not unreasonable for a peptide agonist) and the microscopic association constant for binding is 107 M-1s -1 , the time constant for inhibition of IX(M) would be 10 s at 10 nM BK, which is not far off our 22 s time constant. The long latency in response onset could also be the consequence of a slow rise in the (putative) intracellular messenger, which needs to reach a threshold level before IXIM) is inhibited. Similar concentration-dependent lag times to response were noted by Neher and colleagues for intracellular Ca 2+ elevations in response to agonist activation of transfected muscarinic receptors in neuroblastoma cells (Neher et al., 1988) . Another notable difference between the BK and oxo-M inhibitions of IK(i) is the tachyphylaxis seen only with high concentrations of BK (10 riM), whereby a prior exposure to BK greatly reduced responses to a subsequent agonist application. It could be argued that this tachyphylaxis is not the result of desensitization, as Ix(M) inhibition was maintained during agonist applications that were usually at least 2 min, and often longer. However, we can not exclude the possibility that the apparent tachyphylaxis is in fact a slowly developing desensitization occurring at receptors still occupied by agonist (even though the agonist has been washed out). It is interesting in the context of these slow and poorly reversible effects of BK that Shapiro et al. (1994) have recently reported similar slow onset and offset kinetics and tachyphylaxis for the inhibition of voltage-gated Ca 2+ currents by activation of another peptide receptor, the angiotensin AT1 receptor, in SCG neurons.
To conclude, we have observed a powerful inhibitory action of BK on IK(M) in sympathetic neurons; indeed, BK is the most potent inhibitor of this K + current so far reported. This effect can account for the previously reported excitation of sympathetic neurons (Lewis and Reit, 1965; 1966; Trendelenburg, 1966; Haefely, 1970; Wallis and Woodward, 1974) . It is noteworthy that the concentrations of BK required to inhibit Ix(M) are well within the range of those found in inflammatory exudates (see Regoli and Barabe, 1980) . Hence this effect may well contribute to the suggested role of sympathetic excitation in inflammation (Dray and Perkins, 1993) and pain (McMahon, 1991) .
Experimental Procedures
Cell Culture Superior cervical ganglia were isolated from rats (15-19 days old), and cells were dissociated and cultured for 1-3 days, as described previously (Selyanko et al., 1992) . Cells were plated on grid-marked plastic dishes (coated with laminin) to facilitate localization of injected neurons. For injections and recordings, cells were superfused with a modified Krebs' solution containing 120 mM NaCI, 3 mM KCI, 2.5 mM CaCI2, 1.2 mM MgCI2, 23 mM NaHCO3, 11 mM glucose, 5 mM HEPES, and .5 p.M tetrodotoxin. When bubbled with a mixture of 95% 02/5% CO~, the pH of this solution was 7.36. Experiments were performed at room temperature (20°C-25°C).
Antibody Injections
Antisera for injections were raised in New Zealand white rabbits as described previously (Goldsmith et al., 1987) . Injections were made using high resistance (>30 MQ) electrodes, with the application of gentle pressure to expel the solution. Neurons were injected with one of the following: antiserum raised against the C terminal decapeptide sequence of the Go (z subunit (OC2); antiserum raised against the C-terminal decapeptide sequence common to the G~ and Gll ~ subunits (CQ1); a decapeptide sequence (1 p.g/ml) corresponding to the common C-terminal decapeptide sequence of Gq and GI~ ~ subunits (immunogenic peptide); a combination of CQ1 and immunogenic peptide (1 ~g/ml).
Undiluted antisera, or antisera plus immunogenic peptide were coinjected with a fluorescein isothiocyanate-labeled dextran (FITCdextran; 10 kDa; Molecular Probes) to allow verification of injection using a fluorescence microscope (Nikon Diaphot 300). Only neurons showing bright fluorescence after injection were used for recordings. In initial experiments comparing effects of anti-G~o and anti-Goq~l antibodies, cells were coinjected with 1% FITC-dextran. However, we subsequently found that 0.1% FITC-dextran gave sufficient fluorescence to allow visualization for up to 6 hr postinjection, so we used this concentration in later experiments with injections of CQ1 combined with immunogenic peptide.
IK(a) Recordings
Whole-cell currents were recorded using the amphotericin perforated patch method (Rae et al., 1991) . Patch pipettes (2-5 M~) were frontfilled by dipping the tip into a filtered solution containing 80 mM K-acetate, 30 mM KCI, 3 mM MgCI2, and 40 mM HEPES (adjusted to pH 7.2 and 280 mOsm) for 20-60 s and then back-filled with the same solution containing 50 p,g/ml amphotericin (Sigma; in 0.2o/o dimethyl sulfoxide). After obtaining seals of >2 GQ resistance, permeabilization with amphotericin usually achieved access resistances of <15 MQ. To measure IK(M) amplitude, neurons were voltage clamped using a switching amplifier (Axoclamp 2A or 2B, Axon Instruments; switching frequency 3-6 kHz), at potentials of -20 mV to -30 mV to activate IK(M), and the slow IK(M) deactivation relaxation was revealed by stepping to -55 mV for 1 s. In some experiments, current responses were recorded to voltage ramps between about -110 mV and -20 mV, at a ramp rate of -10 mV/s (from a holding potential of around -20 mV). These experiments were done using external solution containing 1 mM CsCI to block inward rectifier currents activated at potentials more negative than about -90 inV. Voltage command protocols and data acquisition were carried out using pClamp software (Axon Instruments). A liquid junction potential of -6 mV (outside with respect to inside) has not been accounted for in measurements of membrane potential.
Drugs (bradykinin, Bacbem; oxotremorine msthiodide, RBI) were applied directly to the locality of the cell under study via a fine tube (diameter, 50 p,m) positioned about 1 mm from the cell. Prior to application, drug solution was continually removed by vacuum suction applied to a second tube glued alongside the drug application tube. Drug was delivered when the vacuum was released. The time for equilibration of drug concentration at the cell was less than 6 s, as determined by application of a solution containing 37 mM additional KCI (to set the reversal potential for K + at -25 mV) and measuring the delay to negation of the standing outward K + current activated at a holding potential of -25 inV. On reapplying the vacuum, complete recovery of current was seen in under 30 s. All data are presented as mean _+ standard error.
RNA Analysis
RT-PCR were carried out as described by Steel and Buckley (1993) . Sympathetic ganglia and dorsal root ganglia total RNA was extracted according to the method of Chomczynski and Sacchi (1987) . RNA was reverse transcribed using AMV-RT (Seikagaku) and subsequently amplified using Taq polymerase (Promega). The primers used for amplification were derived from cDNA sequence (Mclntyre et al., 1993 ; EMBL database accession number X69682). Primer sequences were: B2 197s, GACATCACCGGCCAGCCCTTG; B2 198as, GGTGACGTT-GAACATTTCGAT. B2 197s was derived from an upstream noncoding exon and B2 198as from the coding exon.
